Macula degeneration Eye Diseases Macula degeneration
Conditions
Interventions
Patients are randomised to one of two treatments:
1. Patients receive Photodynamic Treatment (PDT) on their initial treatment visit. Follow up is every three months for a year with further PDT if requ
Sponsors
King's College Hospital (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age 50 years or older, male and female 2. Clinical diagnosis of age-related macular degeneration (AMD) 3. Subfoveal choroidal neovascularisation (CNV) confirmed by fluorescein angiography 4. Best corrected visual acuity of 35 letters on Early Treatment Diabetic Retinopathy Study (ETDRS) chart
Exclusion criteria
Exclusion criteria: 1. Inability to understand or sign consent form 2. The patient has a current medical condition or history of a medical condition that would be likely to preclude scheduled study visits 3. Patient has a current ophthalmic condition or history of an ophthalmic condition that might compromise the assessment of the treatment 4. Signs of a myopic retina or refraction of greater than -8 dioptres in their current or previous glasses prescription 5. Signs of other retinal conditions that may have caused the CNV such as angioid streaks, choroidal rupture, and old chorio-retinitis 6. Open angle glaucoma 7. At increased risk of developing glaucoma such as having; pigment dispersion syndrome or pseudoexfoliation 8. Unable to have a good quality fluorescein angiogram taken, e.g., due to head tremor or media opacity
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The percentage of less than 15 letter loss at one year. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Percentage of more than 30 letter loss at one year 2. Number of re-treatments required in one year 3. Change in lesion size at one year | — |
Countries
United Kingdom
Outcome results
None listed